Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Owkin, founded in 2016 and headquartered in New York, is an artificial intelligence (AI)-based biotechnology company that leverages AI to enhance drug discovery, accelerate clinical trials, and develop diagnostic tools. The company's innovative approach enables researchers in hospitals, universities, and the biopharmaceutical industry to improve drug development by understanding how drug efficacy varies across patient populations.
Since its inception, Owkin has demonstrated significant growth and attracted substantial investment. The company has raised a total of $334.1 million across multiple funding rounds, with notable investors including Sanofi Ventures, Bristol-Myers Squibb, and Google Ventures. In 2021, Owkin reached a valuation of $1 billion following a $180 million Series B round led by Sanofi Ventures, marking its entry into unicorn status.
Owkin's focus on AI-driven drug development positions it well in the competitive healthcare technology landscape. The company's innovative approach has garnered attention from major pharmaceutical companies, as evidenced by its strategic partnerships and investments.
While there is currently no official information available regarding Owkin's IPO prospects, the company's strong funding history, unicorn status, and strategic partnerships in the pharmaceutical industry could potentially make it an attractive candidate for going public in the future. However, it's important to note that any discussions about a potential IPO remain speculative at this time.
Investors interested in the AI-driven healthcare sector should keep an eye on Owkin's developments, as the company continues to make strides in applying artificial intelligence to drug discovery and development. As with any investment decision, it's crucial to conduct thorough research and consider market conditions before making any financial commitments.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Owkin's IPO prospects remain uncertain, investors interested in gaining exposure to innovative AI-driven healthcare companies don't have to wait. At Linqto, we offer members access to interests in promising pre-IPO private companies like Owkin, potentially allowing you to benefit from their growth before they go public. Our platform enables you to diversify your portfolio with lower minimum investments in emerging leaders in the biotech and AI sectors.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
